Monoclonal Antibody Therapies for Children.
Pediatr Rev
Department of Pediatrics, Ochsner Health System, New Orleans, Louisiana.
Published: March 2025
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1542/pir.2024-006452 | DOI Listing |
Similar Publications
Penile diffuse large B-cell lymphoma in a young man.
BMJ Case Rep
March 2025
Hematology/Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Here, we present the case of a young man active-duty service member diagnosed with stage IE penile diffuse large B-cell lymphoma (DLBCL), germinal centre B-cell (GCB) subtype. Primary penile DLBCL is an exceptionally rare condition, with fewer than 30 cases reported in the medical literature. Notably, this patient is significantly younger than the typical demographic, as extranodal DLBCL affecting the penis usually occurs in elderly men, with a median age of 69 years at diagnosis.
View Article and Find Full Text PDFEarly daratumumab therapy improves renal outcomes in newly diagnosed myeloma patients admitted with kidney injury.
Blood Adv
March 2025
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States.
Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes. Daratumumab, an anti-CD38 monoclonal antibody, has significant clinical efficacy in MM.
View Article and Find Full Text PDFInotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series.
Cancer Rep (Hoboken)
March 2025
Department of Oncology, KU Leuven, Leuven, Belgium.
Background: CD19-directed chimeric antigen receptor T-cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal.
View Article and Find Full Text PDFEfficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis.
Daru
March 2025
Department of Pharmacy, Beijing Hospital; National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences; Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), No. 1 Dahua Road, Dongcheng District, Beijing, 100730, P.R. China.
Background: Rituximab (RTX) is one of the treatment options for refractory myasthenia gravis (MG), yet the optimal dosing schedule remains undetermined. Our study aims to explore this issue and offer a valuable reference for clinical dosing.
Methods: This is a single-arm meta-analysis.
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.
Am J Clin Dermatol
March 2025
Blauvelt Consulting, LLC, Annapolis, MD, USA.
Background And Objective: There is a need for long-term atopic dermatitis (AD) treatments that can effectively improve AD involvement of the head and neck (H&N) region (referred to as H&N AD). Tralokinumab, a high-affinity monoclonal antibody that neutralizes interleukin-13, is approved for the treatment of moderate-to-severe AD. Recent real-world studies have observed the effectiveness of tralokinumab for H&N AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.